These NCR+ILC3s were mainly localized at the edge of tumor-associated tertiary lymphoid structures, to produce IL-22, TNF-a, IL-8, and IL-2, and when activated, are able to activate endothelial cells [149]. The gene discussed is TNF; the disease is neoplasm.